Skip to main content
SpringerLink
Log in

Pharmacological Background

  • Chapter
Regional Cancer Therapy

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

  • 971 Accesses

Abstract

The pharmacological rational for regional cancer therapy is based on delivering a high dose intensity of the chemotherapeutic drug, resulting in an advantageous tumor cure/normal tissue complication differential (high therapeutic ratio). Only patients with an anatomically confined tumor and technical feasibility of antitumor therapy administration are expected to reach clinical benefit. Specific pharmacological characteristics of the delivered drug are of potential additional benefit. The pharmacological background of intraperitoneal chemotherapy, isolated hepatic perfusion, and isolated extremity perfusion are given as an example of the advantages and opportunities of regional anticancer therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Sparreboom A, Danesi R, Ando Y, Chan J, Figg WD. Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resistance Updates 2003;6:71–84.

    Article  PubMed  CAS  Google Scholar 

  2. Guchelaar HJ, Hoekstra HJ, Devries EGE, Uges DRA, Oosterhuis JW, Koops HS. Cisplatin and platinum pharmacokinetics during hyperthermic isolated limb perfusion for human tumors of the extremities. Br J Cancer 1992;65:898–902.

    PubMed  CAS  Google Scholar 

  3. Sugarbaker PH, Mora JT, Carmignani P, Stuart OA, Yoo D. Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy. Oncologist 2005;10:112–122.

    Article  PubMed  CAS  Google Scholar 

  4. Gelderblom H, Verweij J, van Zomeren DM, et al. Influence of Cremophor EL on the bio availability of intraperitoneal paclitaxel. Clin Cancer Res 2002;8:1237–1241.

    PubMed  CAS  Google Scholar 

  5. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001;37:1590–1598.

    Article  PubMed  CAS  Google Scholar 

  6. Sparreboom A, Van Zuylen L, Brouwer E, et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 1999;59:1454–1457.

    PubMed  CAS  Google Scholar 

  7. Knemeyer I, Wientjes MG, Au JLS. Cremophor reduces paclitaxel penetration into bladder wall during intravesical treatment. Cancer Chemother Pharmacol 1999;44:241–248.

    Article  PubMed  CAS  Google Scholar 

  8. Markman M, Rowinsky E, Hakes T, et al. Phase-I trial of intraperitoneal taxol—a Gynecologic Oncology Group Study. J Clin Oncol 1992;10:1485–1491.

    PubMed  CAS  Google Scholar 

  9. Francis P, Rowinsky E, Schneider J, Hakes T, Hoskins W, Markman M. Phase-I feasibility and pharmacological study of weekly intraperitoneal paclitaxe—a Gynecologic-Oncology-Group Pilot-Study. J Clin Oncol 1995;13:2961–2967.

    PubMed  CAS  Google Scholar 

  10. Rothbarth J, Tollenaar RA, Schellens JH, et al. Isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: recent trends and perspectives. Eur J Cancer 2004;40:1812–1824.

    Article  PubMed  CAS  Google Scholar 

  11. Rothbarth J, Vahrmeijer AL, Mulder GJ. Modulation of cytostatic efficacy of melphalan by glutathione: mechanisms and efficacy. Chem Biol Interact 2002; 140:93–107.

    Article  PubMed  CAS  Google Scholar 

  12. Vahrmeijer AL, van Dierendonck JH, Keizer HJ, et al. Increased local cytostatic drug exposure by isolated hepatic perfusion: a phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver. Br J Cancer 2000;82:1539–1546.

    Article  PubMed  CAS  Google Scholar 

  13. Rothbarth J, Woutersen RA, Sparidans RW, van de Velde CJ, Mulder GJ. Melphalan antitumor efficacy and hepatotoxicity: the effect of variable infusion duration in the hepatic artery. J Pharmacol Exp Ther 2003;305:1098–1103.

    Article  PubMed  CAS  Google Scholar 

  14. Sigurdson ER, Ridge JA, Kemeny N, Daly JM. Tumor and liver drug uptake following hepatic artery and portal vein infusion. J Clin Oncol 1987;5:1836–1840.

    PubMed  CAS  Google Scholar 

  15. Rappaport AM. Hepatic blood flow: morphologic aspects and physiologic regulation. Int Rev Physiol 1980;21: 1–63.

    PubMed  CAS  Google Scholar 

  16. Watanabe Y, Puschel GP, Gardemann A, Jungermann K. Presinusoidal and proximal intrasinusoidal confluence of hepatic artery and portal vein in rat liver: functional evidence by orthograde and retrograde bivascular perfusion. Hepatology 1994;19:1198–1207.

    Article  PubMed  CAS  Google Scholar 

  17. Rothbarth J, Sparidans RW, Beijnen JH, et al. Reduced liver uptake of arterially infused melphalan during retrograde rat liver perfusion with unaffected liver tumor uptake. J Pharmacol Exp Ther 2002;303:736–740.

    Article  PubMed  CAS  Google Scholar 

  18. Saltz LB, Cox JV, Blanke C, et al. Irinotecanplus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905–914.

    Article  PubMed  CAS  Google Scholar 

  19. Tournigand C, Andre T, Achille E, et al. FOLFIRI Followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229–237.

    Article  PubMed  CAS  Google Scholar 

  20. Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413–1418.

    Article  PubMed  CAS  Google Scholar 

  21. Raymond E, Chaney SG, Taamma A, Cvitkovic E. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 1998;9:1053–1071.

    Article  PubMed  CAS  Google Scholar 

  22. Hertzberg RP, Caranfa MJ, Holden KG, et al. Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J Med Chem 1989;32:715–720.

    Article  PubMed  CAS  Google Scholar 

  23. Chabot GG, Abigerges D, Catimel G, et al. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann Oncol 1995;6:141–151.

    PubMed  CAS  Google Scholar 

  24. Extra JM, Marty M, Brienza S, Misset JL. Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol 1998;25(2 Suppl 5): 13–22.

    PubMed  CAS  Google Scholar 

  25. Raymond E, Faivre S, Woynarowski JM, Chaney SG. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 1998;25(2 Suppl 5):4–12.

    PubMed  CAS  Google Scholar 

  26. Creech O, Krementz ET, Ryan RF, Winblad JN. Chemotherapy of cancer—regional perfusion utilizing an extracorporeal circuit. Ann Surg 1958;148:616–632.

    Article  PubMed  Google Scholar 

  27. Stehlin JS. Hyperthermic perfusion with chemotherapy for cancers of extremities. Surg Gynecol Obstet Int Abstr Surg 1969;129:305.

    Google Scholar 

  28. Roseman JM, Tench D, Bryant LR. The safe use of cisplatin in hyperthermic isolated limb perfusion systems. Cancer 1985;56:742–744.

    Article  PubMed  CAS  Google Scholar 

  29. Hahn GM. Potential for therapy of drugs and hyperthermia. Cancer Res 1979;39:2264–2268.

    PubMed  CAS  Google Scholar 

  30. Song CW, Kang MS, Rhee JG, Levitt SH. The effect of hyperthermia on vascular function, PH, and cell-survivalval. Radiology 1980;137:795–803.

    PubMed  CAS  Google Scholar 

  31. Alberts DS, Peng YM, Chen HSG, Moon TE, Cetas TC, Hoeschele JD. Therapeutic synergism of hyperthermia-Cis-platinum in A mouse-tumor model. J Natl Cancer Inst 1980;65:455–461.

    PubMed  CAS  Google Scholar 

  32. Herman TS. Temperature-dependence of adriamycin, cis-diamminedichloroplatinum, bleomycin, and l,3-bis(2-chloroethyl)-l-nitrosourea cyto-toxicity in vitro. Cancer Res 1983;43:517–520.

    PubMed  CAS  Google Scholar 

  33. Meyn RE, Corry PM, Fletcher SE, Demetriades M. Thermal Enhancement of DNA damage in mammalian-cells treated with cis-diamminedichloroplatinum(Ii). Cancer Res 1980;40:1136–1139.

    PubMed  CAS  Google Scholar 

  34. Herman TS, Teicher BA, Chan V, Collins LS, Abrams MJ. Effect of heat on the cyto-toxicity and interaction with DNA of a series of platinum complexes. Int J Radiat Oncol Biol Phys 1989; 16:443–449.

    PubMed  CAS  Google Scholar 

  35. Wallner KE, Degregorio MW, Li GC. Hyperthermic potentiation of cis-diamminedichloroplatinum(Ii) cytotoxicity in chinese-hamster ovary cells resistant to the drug. Cancer Res 1986;46:6242–6245.

    PubMed  CAS  Google Scholar 

  36. Cavalier R, Ciocatto EC, Giovanel BC, et al. Selective heat sensitivity of cancer cells—biochemical and clinical studies. Cancer 1967;20:1351.

    Article  Google Scholar 

  37. Kase K, Hahn GM. Differential heat response of normal and transformed human cells in tissue-culture. Nature 1975;255:228–230.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands

    Hans Gelderblom MD

  2. Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands

    Joost Rothbarth MD & Cornelius J. H. van de Velde MD

  3. Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands

    Henk-Jan Guchelaar PharmD

Authors
  1. Hans Gelderblom MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joost Rothbarth MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cornelius J. H. van de Velde MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Henk-Jan Guchelaar PharmD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Robert-Rössle-Hospital and Tumor Institute, Charité University of Medicine, Berlin

    Peter M. Schlag MD (Professor and Head of Surgical Oncology) (Professor and Head of Surgical Oncology)

  2. Max-Delbrück-Center for Molecular Medicine, Berlin, Germany

    Peter M. Schlag MD (Professor and Head of Surgical Oncology) & Ulrike Stein PhD (Assistant Professor) (Professor and Head of Surgical Oncology) &  (Assistant Professor)

  3. Tumor Metastasis and Therapy Response Program, Robert-Rössle-Hospital and Tumor Institute, Charité University of Medicine, Berlin

    Ulrike Stein PhD (Assistant Professor) (Assistant Professor)

  4. Erasmus University MC—Daniel den Hoed Cancer Center, Rotterdam, The Netherlands

    Alexander M. M. Eggermont MD, PhD (Professor and Head of Surgical Oncology) (Professor and Head of Surgical Oncology)

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Gelderblom, H., Rothbarth, J., van de Velde, C.J.H., Guchelaar, HJ. (2007). Pharmacological Background. In: Schlag, P.M., Stein, U., Eggermont, A.M.M. (eds) Regional Cancer Therapy. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1007/978-1-59745-225-0_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-225-0_2

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-672-6

  • Online ISBN: 978-1-59745-225-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation